>
>
PARIS–(BUSINESS WIRE)–Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to
PARIS–(BUSINESS WIRE)–Regulatory News: Nanobiotix (Paris:NANO)(NASDAQ:NBTX) Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com Date
PARIS–(BUSINESS WIRE)–Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: This replaces the announcement made at 4:40PM EDT/20:40 CEST on May 18 due to the following correction: Updated date
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company“), a late-clinical stage biotechnology company pioneering physics-based approaches to expand
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the “Company“), a clinical-stage biotechnology company pioneering physics-based approaches to expand
